BioSpace News Archive

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately.

Gritstone bio, Inc. announced that it will report its financial results for the first quarter ended March 31, 2022 and provide recent clinical and corporate updates via a press release on Thursday, May 5, 2022 at 4:05pm Eastern Time.

HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously announced Phase 2b clinical trial of HIL-214, the company’s virus-like particle (VLP) based vaccine candidate, for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection in infants.

Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of avasopasem evaluating its ability to reduce the incidence of severe acute radiation-induced esophagitis in patients with lung cancer receiving concurrent chemoradiotherapy.

Roivant Sciences (Nasdaq: ROIV) today announced that Srini Ramanathan, Ph.D. will be joining the company as Chief Development Officer.

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, “Junshi”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (“FDA”, “the Agency”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”) for toripalimab in combination with gemcitabine and cisplatin.

InMode Ltd. announced its consolidated financial results for the first quarter ended March 31, 2022.

Alkermes plc (Nasdaq: ALKS) today announced plans to present research related to its psychiatry portfolio at four scientific conferences during Mental Health Awareness Month in May.

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the first quarter of 2022, at 8:00 a.m. EST on Thursday , May 12, 2022.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.